Etcembly | TCRs by intelligent design

Pioneers in

combining machine

and human intelligence

to deliver best-in-class immunotherapies

Accelerate
the path
to clinic

One of the
top 15 techbio
start-ups as mentioned
by Sifted

Unlock new
targets from
the immune
repertoire

See the
Latest news

Click to read more about the
LONG TERM SURVIVORS
STUDY

Etcembly’s vision is to be the leader in mapping human immune repertoires, empowering humanity to predict, prevent and conquer diseases with unprecedented precision.

Harnessing the immunesystem for a cancer-free future

ADVANCING IMMUNOTHERAPY THROUGH
DEEP REPERTOIRE SEQUENCING

We’re inviting people who are living with or have survived cancer as well as healthy volunteers to participate in a research study to help us develop new treatments that harness the power of a patient’s own immune system to fight the disease.

OUR CHALLENGE

We aim to explore the unique immune drivers that contribute to cancer survival. By analyzing the immune repertoires of long-term survivors, we can uncover critical insights that will pave the way for new therapeutic strategies. Our goal is to engineer T Cell Receptors (TCRs) and antibodies that target cancer more effectively, using our cutting-edge platform, EMLy.

Long Term Survivors Study

More about EMLy

What we do

DEEP REPERTOIRE SEQUENCING

We utilize sophisticated sequencing technologies to analyze the immune repertoires of long-term cancer survivors, capturing the complexity and diversity of their immune responses.

LARGE LANGUAGE MODELS

By applying our industry leading large language models, we interpret vast datasets to identify patterns and correlations within immune responses, enhancing our understanding of cancer immunology.

ENGINEERING TCRS AND ANTIBODIES

Our platform, EMLy, enables us to design and optimize TCRs and antibodies that can be used in immunotherapy, offering new hope for cancer treatment.

More about EMLy

Why it matters

Cancer survivors possess unique immune profiles that can reveal invaluable information about effective immune responses. By focusing on these individuals, we aim to develop targeted therapies that not only enhance survival but also improve the quality of life for patients worldwide.